Alvotech Strikes $45m Deal With Yas Holding
Biosimilars Deal Includes 2.5% Stake And MENA Rights
Alvotech has struck an investment deal worth $45m that will give Yas Holding a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.
You may also be interested in...
Egypt has become the latest market in which Alvotech has received approval for its AVT02 biosimilar adalimumab rival to Humira. The product will be marketed by MENA partner Bioventure.
Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.
Three firms across Europe and North Africa sign to sell Alvotech biosimilar candidates in 19 MENA countries as the Icelandic developer shifts focus from R&D to global commercialization.